SG10202009852PA - Novel aav8 mutant capsids and compositions containing same - Google Patents
Novel aav8 mutant capsids and compositions containing sameInfo
- Publication number
- SG10202009852PA SG10202009852PA SG10202009852PA SG10202009852PA SG10202009852PA SG 10202009852P A SG10202009852P A SG 10202009852PA SG 10202009852P A SG10202009852P A SG 10202009852PA SG 10202009852P A SG10202009852P A SG 10202009852PA SG 10202009852P A SG10202009852P A SG 10202009852PA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions containing
- containing same
- mutant capsids
- novel
- aav8 mutant
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Knitting Of Fabric (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323389P | 2016-04-15 | 2016-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202009852PA true SG10202009852PA (en) | 2020-11-27 |
Family
ID=60042790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009852PA SG10202009852PA (en) | 2016-04-15 | 2017-04-13 | Novel aav8 mutant capsids and compositions containing same |
| SG11201808812RA SG11201808812RA (en) | 2016-04-15 | 2017-04-13 | Novel aav8 mutant capsids and compositions containing same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808812RA SG11201808812RA (en) | 2016-04-15 | 2017-04-13 | Novel aav8 mutant capsids and compositions containing same |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11091776B2 (en) |
| EP (1) | EP3443108A4 (en) |
| JP (2) | JP7140683B2 (en) |
| CN (1) | CN109661470A (en) |
| AU (2) | AU2017248656B2 (en) |
| CA (1) | CA3019423A1 (en) |
| IL (2) | IL298604A (en) |
| SG (2) | SG10202009852PA (en) |
| WO (1) | WO2017180854A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| MX2017006217A (en) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Modulatory polynucleotides. |
| US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| HK1245326A1 (en) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| JP6929791B2 (en) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | Compositions and methods for epigenome editing |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| ES2865487T3 (en) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Methods and compositions for viral vectors that evade antibodies |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| WO2017095967A2 (en) | 2015-11-30 | 2017-06-08 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| WO2017096162A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| KR20240056729A (en) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | Modulatory polynucleotides |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| AU2018261790B2 (en) | 2017-05-05 | 2024-10-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| JP2020530307A (en) * | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | Adeno-associated virus vector for gene therapy |
| EP3758724A4 (en) * | 2018-02-27 | 2022-07-06 | The Trustees of The University of Pennsylvania | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSID DEAMIDATION AND USES THEREOF |
| US12416016B2 (en) * | 2018-02-27 | 2025-09-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor |
| KR102597383B1 (en) * | 2018-03-20 | 2023-11-01 | 다이오 페이퍼 코퍼레이션 | Tape type disposable diaper |
| JP2021519581A (en) | 2018-04-03 | 2021-08-12 | ストライドバイオ，インコーポレイテッド | Viral vector to avoid antibodies |
| AU2019247191A1 (en) | 2018-04-03 | 2020-10-15 | Ginkgo Bioworks, Inc. | Virus vectors for targeting ophthalmic tissues |
| SG11202009452WA (en) * | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| US12460226B2 (en) | 2018-04-16 | 2025-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating duchenne muscular dystrophy |
| TW202005978A (en) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | Novel liver targeting adeno-associated viral vectors |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| US20210292373A1 (en) * | 2018-07-10 | 2021-09-23 | University Of Florida Research Foundation, Incorporated | Aav vp1u chimeras |
| AU2019346655B2 (en) | 2018-09-28 | 2025-03-13 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020072451A1 (en) | 2018-10-01 | 2020-04-09 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating propionic acidemia |
| AU2019428629A1 (en) * | 2019-02-06 | 2021-01-28 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
| AR118465A1 (en) | 2019-03-21 | 2021-10-06 | Stridebio Inc | RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS |
| EP3969061A1 (en) * | 2019-05-14 | 2022-03-23 | BioMarin Pharmaceutical Inc. | Methods of redosing gene therapy vectors |
| US20220265853A1 (en) * | 2019-07-12 | 2022-08-25 | Gene Therapy Research Institution Co., Ltd. | Adeno-associated virus virion for gene transfer to human liver |
| CN110423281B (en) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | Fusion protein, viral vector and drug for treating age-related macular degeneration |
| WO2021030764A1 (en) * | 2019-08-14 | 2021-02-18 | University Of Florida Research Foundation, Incorporated | Aav capsid variants for gene therapy |
| CA3157700A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| JP2023520402A (en) | 2020-03-31 | 2023-05-17 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Gene therapy to treat propionic acidemia |
| US20230348870A1 (en) * | 2020-04-27 | 2023-11-02 | Duke University | Gene editing of satellite cells in vivo using aav vectors encoding muscle-specific promoters |
| US20230048732A1 (en) * | 2020-05-26 | 2023-02-16 | Shape Therapeutics Inc. | High throughput engineering of functional aav capsids |
| EP4176064A1 (en) * | 2020-07-03 | 2023-05-10 | Genethon | Method for engineering novel hybrid aav capsids through hypervariable regions swapping |
| CA3189878A1 (en) | 2020-08-19 | 2022-02-24 | Colin O'BANION | Adeno-associated virus vectors for treatment of rett syndrome |
| BR112023015303A2 (en) | 2021-02-01 | 2023-11-14 | Regenxbio Inc | METHOD TO TREAT CLN2 DISEASE DUE TO TPP1 DEFICIENCY IN A SUBJECT |
| GB202202842D0 (en) | 2022-03-01 | 2022-04-13 | Belgian Volition Srl | Chimeric antigen receptor T-cell treatments targeted to chromatin fragments and extracellular traps |
| US20250108127A1 (en) * | 2022-08-29 | 2025-04-03 | Shanghai Ophthal-Bright Biomedicine Technology | Modified vector, construction method, and application of modified aav-8 serotype for gene targeting and expression |
| WO2024143440A1 (en) * | 2022-12-28 | 2024-07-04 | 富士フイルム株式会社 | Method for producing adeno-associated virus, and vector set |
| CN118956906B (en) * | 2024-10-17 | 2025-03-25 | 杭州嘉因生物科技有限公司 | A virus packaging plasmid and its application |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| ATE317916T1 (en) * | 2001-11-13 | 2006-03-15 | Univ Pennsylvania | METHOD FOR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND KIT FOR IMPLEMENTING THE METHOD |
| EP1453547B1 (en) | 2001-12-17 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| ES2874298T3 (en) * | 2003-09-30 | 2021-11-04 | Univ Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing the same, and uses thereof |
| ES2428218T3 (en) * | 2005-04-07 | 2013-11-06 | The Trustees Of The University Of Pennsylvania | AAV rh48 modified capsules, compositions containing them and uses thereof |
| US20090191597A1 (en) | 2006-01-20 | 2009-07-30 | Asklepios Biopharmaceutical, Inc. | Enhanced production of infectious parvovirus vectors in insect cells |
| EP2287323A1 (en) | 2009-07-31 | 2011-02-23 | Association Institut de Myologie | Widespread gene delivery to the retina using systemic administration of AAV vectors |
| WO2011038187A1 (en) | 2009-09-25 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom |
| US20130023033A1 (en) | 2010-03-29 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| WO2013155222A2 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Brain-specific enhancers for cell-based therapy |
| JP6199965B2 (en) | 2012-07-11 | 2017-09-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | AAV-mediated gene therapy for RPGRX-linked retinal degeneration |
| WO2014124282A1 (en) * | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
-
2017
- 2017-04-13 AU AU2017248656A patent/AU2017248656B2/en not_active Ceased
- 2017-04-13 WO PCT/US2017/027392 patent/WO2017180854A1/en not_active Ceased
- 2017-04-13 IL IL298604A patent/IL298604A/en unknown
- 2017-04-13 CN CN201780037134.2A patent/CN109661470A/en active Pending
- 2017-04-13 SG SG10202009852PA patent/SG10202009852PA/en unknown
- 2017-04-13 JP JP2018554344A patent/JP7140683B2/en active Active
- 2017-04-13 EP EP17783123.7A patent/EP3443108A4/en active Pending
- 2017-04-13 US US16/093,800 patent/US11091776B2/en active Active
- 2017-04-13 SG SG11201808812RA patent/SG11201808812RA/en unknown
- 2017-04-13 CA CA3019423A patent/CA3019423A1/en active Pending
-
2018
- 2018-10-08 IL IL262214A patent/IL262214B2/en unknown
-
2021
- 2021-07-12 US US17/373,485 patent/US20210340569A1/en active Pending
-
2022
- 2022-06-02 JP JP2022090027A patent/JP2022116275A/en active Pending
-
2023
- 2023-06-29 AU AU2023204146A patent/AU2023204146A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201808812RA (en) | 2018-11-29 |
| US20210340569A1 (en) | 2021-11-04 |
| AU2023204146A1 (en) | 2023-09-07 |
| AU2017248656B2 (en) | 2023-07-27 |
| CN109661470A (en) | 2019-04-19 |
| IL262214A (en) | 2018-11-29 |
| AU2017248656A1 (en) | 2018-10-18 |
| CA3019423A1 (en) | 2017-10-19 |
| JP7140683B2 (en) | 2022-09-21 |
| JP2019513401A (en) | 2019-05-30 |
| US20190078119A1 (en) | 2019-03-14 |
| WO2017180854A1 (en) | 2017-10-19 |
| IL298604A (en) | 2023-01-01 |
| US11091776B2 (en) | 2021-08-17 |
| IL262214B1 (en) | 2023-01-01 |
| EP3443108A1 (en) | 2019-02-20 |
| EP3443108A4 (en) | 2019-11-20 |
| IL262214B2 (en) | 2023-05-01 |
| JP2022116275A (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262214A (en) | Novel aav8 mutant capsids and compositions containing same | |
| IL268970A (en) | Novel compositions and methods | |
| EP3528785A4 (en) | Modified aav capsids and uses thereof | |
| ZA201807668B (en) | Compositions and methods for dust control and the manufacture of construction materials | |
| EP3589277A4 (en) | Modified aav capsids and uses thereof | |
| IL264446A (en) | Compounds and compositions and uses thereof | |
| ZA201803451B (en) | Probiotic compositions and uses thereof | |
| PL3122448T3 (en) | Dispersions containing encapsulated materials and compositions using same | |
| GB2556619B (en) | Suspension compositions | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| ZA201807267B (en) | Cosmetic material compositions | |
| PL4245896T3 (en) | New polyester and compositions containing it | |
| GB202201861D0 (en) | Novel methods and compositions | |
| SG11201710212UA (en) | Uv-blocking cosmetic composition | |
| PL3576846T3 (en) | Sunscreen composition | |
| EP3193637A4 (en) | Improved drink stabilizer composition and stabilized drink compositions | |
| PL3463259T3 (en) | Sunscreen compositions | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| GB201717826D0 (en) | Sunscreen compositions | |
| ZA201802565B (en) | New adjuvant and vaccine composition containing the same | |
| PL3568203T3 (en) | Compounds and compositions | |
| GB201603591D0 (en) | Improved promotors and compositions | |
| GB2570376B (en) | Suspension compositions | |
| IL269723A (en) | Mutant alpha-1-antitrypsin compositions and use thereof | |
| GB201602409D0 (en) | Compositions and uses thereof |